Genetic
research in alopecia areata
Several research groups have been
examining the genetic make up of people who develop alopecia areata.
It is generally believed that alopecia areata susceptibility is
polygenic. That means there are a number of genes which, if present,
make that individual more likely to develop alopecia areata. The
triggers for the onset of alopecia areata may be environmental
but
susceptibility towards alopecia areata development, the resistance
of the alopecia areata lesion to treatment, its persistence, regression,
and its extent over the body are probably influenced by the interaction
of several genes. Individuals need not have all the susceptibility
genes but the more you have the worse the prognosis. Alopecia areata
is described as “polygenic” because several genes are
probably involved.
 Human leukocyte antigen (HLA) genes on human chromosome 6 code
for the major histocompatibility complex (MHC) proteins that are
important in presentation of antigens and self recognition by immune
cells. MHC class I antigens comprise the HLA-B, HLA-C and HLA-A
loci in this order. MHC class II is coded by genes in the HLA-D
region that is subdivided into gene clusters HLA-DP, HLA-DQ, and
HLA-DR (Vogel 1997).
Genetic research into other autoimmune diseases has shown HLA
encoding alleles to segregate with specific disease phenotypes.
However, inconsistent results have been found with analysis of HLA
class I haplotypes of the A and B series and AA. Some studies report
statistically significant associations, but other studies found
no HLA class I association (Kuntz 1977, Zlotogorski 1990). HLA-A2,
B40 and Aw32, B18 have each been reported as associated with AA
(Hordinsky 1984, Valsecchi 1985). Association between HLA-B12 in
Finnish patients, HLA-B18 in Israelis, B13 and B27 in Russians has
also been suggested (Kianto 1977, Hacham-Zadeh 1981, Averbakh 1986).
Genetic analysis studies in AA have primarily focused on the HLA-D
genes (MHC class II encoding) as the most likely region for genes
that regulate susceptibility, severity or resistance to disease
(Duvic 1991). Consistent associations have been observed between
class II haplotypes and AA including DR4 (Frentz 1986, Friedman
1985, Orecchia 1987, Duvic 1991, de Andrade 1999), DR5 (Frentz 1986,
Orecchia 1987), DR6 (de Andrade 1999), DR7 (Averbakh 1986) and broad
antigen DQ3 (Colombe 1995, Welsh 1994, Colombe 1999). More recent
research has shown allele DRB1*1104 (DR11) to be present with significant
increased expression in patients with AA (Colombe 1995, Colombe
1999) and its increased prevalence has been confirmed in other studies
(Duvic 1995, Morling 1990, Welsh 1994). Allele DRB1*0401 (DR4) was
strongly associated with extensive AA totalis or universalis sub-groups
(Colombe 1999). DQB1*0301 (DQ7 by serology) was also significantly
expressed only in association with AA totalis and universalis (Colombe
1995, Duvic 1995, Colombe 1999) and other studies implicate other
DQB1 alleles, DQB1*302, DQB1*601, and DQB1*603, in AA (de Andrade
1999). The general current consensus is that AA in humans has a
genetic basis, but is poorly penetrant within families (Colombe
1995, van der Steen 1992). Aberrant expression of MHC proteins within
AA affected hair follicles is frequently apparent, but the question
of their true significance remains (Messenger 1985, Bröcker
1987). There are many more alleles that code for other factors in,
and outside of, the immune system that may be vital in the development
of AA.
The function of these HLA genes is to make a cell surface protein
structure called the "major histocompatibility complex"
(MHC). These structures are used to introduce antigens to lymphocyte
immune cells. The lymphocytes feel the MHC and the antigen. If the
cells find the antigen stimulating they will respond and target
that antigen wherever they find it in the body. MHC class I antigens
are expressed on almost all nucleated cells in our bodies. Some
lymphocytes (CD8 positive) have the capacity to recognize cellular
antigens presented in association with MHC class I via their T cell
receptors. In contrast, MHC class II antigens are normally expressed
on antigen presenting cells (APCs), such as macrophages and Langerhans'
cells, and expression may be induced on other nucleated cells during
inflammatory processes such as alopecia areata (Messenger 1985,
Bröcker 1987). CD4 positive lymphocytes may recognize antigen
plus MHC class II complexes on APCs.
It might be that certain types of MHC structure are better at
presenting hair follicle antigens to lymphocytes than others. Those
people with HLA genes coding for the MHC structures that are better
able to present hair follicle antigens may be that much more susceptible
to development of alopecia areata. There is laboratory evidence
to support this hypothesis in autoimmune disease but there is no
evidence to demonstrate this is actually possible in alopecia areata.
Analysis of genes in humans is mostly limited to the HLA region
although other groups are looking at genes involved in cytokine
production and activity (cytokines are hormone like communication
molecules that cells use to stimulate each other). The HLA region
is the natural place to start in humans because we know most about
the genes there and what they do. The importance of the HLA genes
identified right now is that they are simply a marker of susceptibility.
It is suspected they are relatively minor genes in alopecia areata
susceptibility. However, the genes could be used to develop a screening
assay that dermatologists could use to identify those most at risk
from developing alopecia areata. Right now that doesn't help people
much but if we eventually identify environmental triggers for onset
of alopecia areata then people known as susceptible because they
have the genes could be advised to avoid the potential triggers.
The NAAF are currently recruiting individuals with a family history
of alopecia areata to provide blood samples for use in genetic research.
The aim is to define more genetic markers common to people with
alopecia areata. Contact NAAF for details.
What
is a polygenic disease
Alopecia areata is described as a polygenic dominant condition
with partial penetrance. Essentially this means that there are several
genes that code for alopecia areata susceptibility that can be transferred
from parent to offspring but that even if an individual has all
the susceptibility genes they may still not actually develop hair
loss.
These genes are probably not mutations or defective genes they
are most likely normal functioning genes. Some or all of the genes
may be quite common in the general population but when several genes
come together and combine forces in an individual they make that
person more susceptible to development of alopecia areata. Each
gene has a different weight or importance in promoting susceptibility.
Some genes will carry a lot of weight and be major alopecia areata
susceptibility genes. Other genes will have little weight and only
contribute in a minor way to susceptibility.
Just having one or two genes may not be enough for susceptibility
to alopecia areata to be significant and people with a couple of
genes may just be carriers. Three or four genes in one person and
perhaps a very strong environmental trigger could induce alopecia
areata. Five or six genes and a mild environmental trigger can induce
alopecia areata. Seven or eight genes and development of alopecia
areata is almost guaranteed after the slightest environmental trigger.
We might also look at genes and extent of the disease. The more
genes the more extensive the hair loss or the more persistent the
alopecia areata is.
Let's say two individuals who did not have alopecia areata but
were carriers for one or two of these genes had children. If they
both give their susceptibility genes to the child the child has
more susceptibility genes than the parents. The child is more susceptible
than the parent and may develop alopecia areata after an environmental
trigger. If this individual then has children with another person
who does not carry any of the susceptibility genes then these children
will have fewer susceptibility genes than the affected parent. The
result is that the alopecia areata trait may be lost from the family
tree. Genetic inheritance along these lines would help explain why
alopecia areata pops up and disappears again in a family tree. The
apparent almost random expression of alopecia areata within families
and in the general population is typical of a polygenic partially
penetrant disease.
Alopecia areata will be difficult to analyze. With every additional
susceptibility gene involved finding the genes becomes exponentially
more complex. I hazard a guess at 5 major genes being involved in
alopecia areata other than those that have been identified in the
HLA region. Several more minor genes will be involved in severity
and susceptibility but we need to concentrate on the big ones first.
Depending on what susceptibility genes are identified and what they
do there could be new opportunities to develop treatments that block
or modify the gene activity. Gene therapy for alopecia areata is
many years in the future though.
Genetic
research in alopecia areata references
- Colombe
BW, Price VH, Khoury EL, Garovoy MR, Lou CD. HLA class II antigen
associations help to define two types of alopecia areata. J Am
Acad Dermatol. 1995 Nov;33(5 Pt 1):757-64.
- van der
Steen P, Traupe H, Happle R, Boezeman J, Strater R, Hamm H. The
genetic risk for alopecia areata in first degree relatives of
severely affected patients. An estimate. Acta Derm Venereol. 1992
Sep;72(5):373-5.
- Messenger
AG, Bleehen SS. Expression of HLA-DR by anagen hair follicles
in alopecia areata. J Invest Dermatol. 1985 Dec;85(6):569-72.
- Brocker
EB, Echternacht-Happle K, Hamm H, Happle R. Abnormal expression
of class I and class II major histocompatibility antigens in alopecia
areata: modulation by topical immunotherapy. J Invest Dermatol.
1987 May;88(5):564-8.
- Hacham-Zadeh
S, Brautbar C, Cohen CA, Cohen T. HLA and alopecia areata in Jerusalem.
Tissue Antigens. 1981 Jul;18(1):71-4.
- Duvic M,
Hordinsky MK, Fiedler VC, O'Brien WR, Young R, Reveille JD. HLA-D
locus associations in alopecia areata. DRw52a may confer disease
resistance. Arch Dermatol. 1991 Jan;127(1):64-8.
- Orecchia
G, Belvedere MC, Martinetti M, Capelli E, Rabbiosi G. Human leukocyte
antigen region involvement in the genetic predisposition to alopecia
areata. Dermatologica. 1987;175(1):10-4.
- de Andrade
M, Jackow CM, Dahm N, Hordinsky M, Reveille JD, Duvic M. Alopecia
areata in families: association with the HLA locus. J Investig
Dermatol Symp Proc. 1999 Dec;4(3):220-3.
- Welsh EA,
Clark HH, Epstein SZ, Reveille JD, Duvic M. Human leukocyte antigen-DQB1*03
alleles are associated with alopecia areata. J Invest Dermatol.
1994 Dec;103(6):758-63.
- Colombe
BW, Lou CD, Price VH. The genetic basis of alopecia areata: HLA
associations with patchy alopecia areata versus alopecia totalis
and alopecia universalis. J Investig Dermatol Symp Proc. 1999
Dec;4(3):216-9.
- Colombe
BW, Price VH, Khoury EL, Garovoy MR, Lou CD. HLA class II antigen
associations help to define two types of alopecia areata. J Am
Acad Dermatol. 1995 Nov;33(5 Pt 1):757-64.
- Vogel F, Motulsky AG. Human Genetics: problems
and approaches. 3rd Edition. Berlin: Springer-Verlag, 1997: 223-6.
- Kuntz BM, Selzle D, Braun-Falco O, Scholz
S, Albert ED. HLA antigens in alopecia areata. Arch Dermatol.
1977 Dec;113(12):1717.
- Zlotogorski A, Weinrauch L, Brautbar C.
Familial alopecia areata: no linkage with HLA. Tissue Antigens.
1990 Jul;36(1):40-1.
- Kianto U, Reunala T, Karvonen J, Lassus
A, Tiilikainen A. HLA-B12 in alopecia areata. Arch Dermatol. 1977
Dec;113(12):1716.
- Averbakh EV, Pospelov LE. [HLA antigens
of patients with alopecia areata]. Vestn Dermatol Venerol. 1986;(1):24-6.
- Frentz G, Thomsen K, Jakobsen BK, Svejgaard
A. HLA-DR4 in alopecia areata. J Am Acad Dermatol. 1986 Jan;14(1):129-30.
- Friedman PS. Clinical and immunologic association
of alopecia areata. Semin dermatol 1985; 4: 9-15.
- Duvic M, Welsh EA, Jackow C, Papadopoulos
E, Reveille JD, Amos C. Analysis of HLA-D locus alleles in alopecia
areata patients and families. J Invest Dermatol. 1995 May;104(5
Suppl):5S-6S.
|
